| Patient | Joe Frazier |
|---|---|
| Date of birth | 1962-01-12 |
| Identifiers | MRN HR-BX004-SYN; SSN (made up) 000-04-5590 |
| Document date | 2026-05-18 |
| Author | Clarence Whitfield, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Three-month review: A1c, blood pressure, weight and semaglutide dose. [S]
Mr. Frazier returns five weeks after his eight-week review. He has taken semaglutide 0.5 mg weekly for seven weeks without nausea. He takes amlodipine 10 mg; home readings average 128/78, and he has no ankle swelling. He has had no alcohol. He has lost 4.1 kg since intake. He missed his eye clinic appointment because it fell on the evening of a fight card at his gym, and it has not yet been rebooked. [S]
| Element | Detail |
|---|---|
| Semaglutide | 0.5 mg weekly for seven weeks; no side effects |
| Home blood pressure | Average 128/78 on amlodipine 10 mg |
| Weight | 99.9 kg, down 4.1 kg |
| Eye examination | Missed; not rebooked |
| System | Result | Finding |
|---|---|---|
| Eyes | Negative | No new blurring or floaters in the right eye |
| Gastrointestinal | Negative | No nausea or abdominal pain |
| Cardiovascular | Negative | No ankle swelling |
3 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin 1000 mg oral tablet, one tablet twice daily with meals; taken for years | One tablet twice daily with meals | Oral route | 2026-02-16 | active | S |
| Lisinopril 20 mg oral tablet, one tablet daily; taken for years | One tablet daily | Oral route | 2026-02-16 | active | S |
| Atorvastatin 40 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-02-16 | active | S |
| Amlodipine 5 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-02 to 2026-04-13 | completed | S |
| Amlodipine 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-04-13 | active | S |
| Semaglutide pen (0.25 mg or 0.5 mg per dose), 0.25 mg under the skin once weekly for four weeks, then 0.5 mg once weekly | 0.25 mg weekly for four weeks, then 0.5 mg weekly | Subcutaneous route | 2026-03-02 to 2026-05-18 | completed | S |
| Semaglutide pen (1 mg per dose), 1 mg under the skin once weekly | 1 mg once weekly | Subcutaneous route | 2026-05-18 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-05-18 | Body height | 182 | cm | S |
| 2026-05-18 | Body weight | 99.9 | kg | S |
| 2026-05-18 | Body mass index (BMI) [Ratio] | 30.2 | kg/m2 | S |
| 2026-05-18 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-05-18 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-05-18 | Heart rate | 74 | /min | S |
| 2026-05-18 | Respiratory rate | 16 | /min | S |
| 2026-05-18 | Body temperature | 36.6 | Cel | S |
| 2026-05-18 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-05-18 | Hemoglobin A1c/Hemoglobin.total in Blood | 7.3 | % | Below 5.7% is normal; goal below 7% for him | High | S |
Vital signs recorded on 2026-05-18; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 126/78, pulse 74; weight 99.9 kg, BMI 30.2 |
| Cardiovascular | No ankle edema |
| Abdomen | Soft; no ascites |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Type 2 diabetes with hyperglycemia, about twelve years' duration, A1c 8.4% on metformin; synthetic modern episode linked to his publicly reported diabetes | active | confirmed | E11.65 | S — Synthetic modern diagnosis; diabetes was reported publicly during his life, but its duration and treatment here are synthetic. |
| Hypertension above goal on lisinopril (152/92 mmHg in the clinic); synthetic modern episode linked to his publicly reported high blood pressure | active | confirmed | I10 | S — Synthetic modern diagnosis; high blood pressure was reported publicly during his life. |
| Raised AST (48 U/L) with mildly low platelets (138) and a FIB-4 score of 3.43 at the yearly liver check, to be evaluated | resolved | confirmed | R74.01 | S — Synthetic presenting finding, superseded at the two-week visit by the elastography and ultrasound diagnosis. |
| Metabolic dysfunction-associated steatotic liver disease (MASLD): steatosis on elastography (controlled attenuation parameter 318 dB/m) and ultrasound, with diabetes, obesity, low HDL and high triglycerides, and little alcohol | active | confirmed | K76.0 | S — Synthetic modern diagnosis. Not part of the public record of his life; chosen to teach surveillance. |
| Compensated cirrhosis (compensated advanced chronic liver disease) from MASLD: liver stiffness 17.6 kPa, platelets 138, nodular liver surface and a spleen of 13.4 cm on ultrasound; no ascites, encephalopathy, bleeding or jaundice; Child-Pugh A | active | confirmed | K74.69 | S — Synthetic modern diagnosis. Not part of the public record of his life; the liver cancer diagnosed three years later in the true frame does not appear in the modern episode. |
| Hyperlipidemia: LDL 132 mg/dL, HDL 38 and triglycerides 210, not on a statin | active | confirmed | E78.5 | S — Synthetic laboratory finding. |
| Obesity, class 1 (BMI 31.4) | active | confirmed | E66.811 | S — Synthetic finding; described without stigma. |
| Reduced vision in the left eye since a cataract found at 20 (counting fingers at 1 meter); right eye 20/30 | active | confirmed | H54.62 | S — Synthetic modern measurement anchored to the documented cataract in his left eye. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Hemoglobin A1c | Every 3 months until at goal or after a change in treatment, then every 6 months | Completed today | 7.3% from 8.4% |
| Examination | Blood pressure (clinic and home), weight and BMI | Every visit | Completed today | 126/78 in the clinic; home average 128/78; weight 99.9 kg |
| Medication safety | Semaglutide dose steps, nausea, abdominal pain, gallbladder and pancreatitis symptoms | At each dose step | Completed today | 0.5 mg for seven weeks without side effects; increased to 1 mg |
| Medication safety | Low blood sugar review and medicine tolerability | Every visit | Completed today | No low blood sugar |
| Examination | Dilated eye examination | At the start of care, then every 1 to 2 years; promptly when A1c is falling quickly on a GLP-1 receptor agonist | Deferred | Planned at intake but not done three months later: he missed the appointment, and it was not rebooked. No harm is known: he has no new eye symptoms, and the later examination found no retinopathy. Corrective action: the clinic rebooked it on a day he chose, with a reminder call, before the A1c falls further |
| Laboratory | Potassium, creatinine and eGFR (CKD-EPI 2021) on lisinopril | Every 6 months on an ACE inhibitor, and after changes | Up to date | Stable five weeks ago; next at seven months |
| Imaging | Liver ultrasound with AFP for hepatocellular carcinoma surveillance | Every 6 months in cirrhosis | Up to date | Next in September |
| Self-management | Weight loss of 7 to 10% | Each visit | Completed today | 4% so far |
| Self-management | Alcohol abstinence | Every visit | Completed today | No alcohol |
| Self-management | Diabetes self-management education | At the start of care and yearly | Completed today | Series of classes completed |
Goal progress:
Guideline basis: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (2026); 12. Retinopathy, Neuropathy, and Foot Care: Standards of Care in Diabetes-2026 (2026); 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2025); AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease (now metabolic dysfunction-associated steatotic liver disease) (2023); AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023); CMID: Clinical Monitoring Intelligence Database, diabetes type 2, hypertension and hyperlipidemia monographs (2026)
Follow-up: Eye clinic next month. Preventive visit in eight weeks. Seven-month review in September with the surveillance ultrasound and AFP. Next scheduled visit 2026-07-13: periodic adult preventive visit. [S]